Skip to content
HeyJared

NeuroFrontiers

Clinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all.

Podcast · By ReachMD · English · Official site

Indexed episodes, last 90 days
3
Latest publication
Aug 31, 2026
Audience
Checking…
Earliest in this view
Jul 17, 2026
The latest indexed work is over 30 days old. There may be a gap in what we hold.

Latest episodes

  1. Episode · Aug 31, 2026

    Can We Delay Alzheimer's Symptoms Before They Begin? Inside the PrevenTRON Trial (opens the original)

    Episode notes

    Read excerpt

    No Label: Geoff Kerchner, MD, PhD Dr. Geoff Kerchner, Vice President and Global Head of Neurodegeneration at Roche, Basel, Switzerland, discusses the science behind PrevenTRON, a prevention study evaluating trontinemab in individuals with preclinical Alzheimer disease.

  2. Episode · Aug 20, 2026

    Subcutaneous Lecanemab for Early Alzheimer Disease: Evidence, Safety, and Patient Selection (opens the original)

    Episode notes

    Read excerpt

    No Label: Michael Irizarry, MD, MPH Dr. Michael Irizarry, Senior Vice-President, Clinical Research, Eisai, Nutley, NJ, discusses the evidence supporting subcutaneous lecanemab for early Alzheimer disease, including dosing, amyloid clearance, and safety monitoring.

  3. Episode · Jul 17, 2026

    Next-Generation CNS Drug Delivery: Brainshuttle Technology and Clinical Implications in Alzheimer Disease (opens the original)

    Episode notes

    Read excerpt

    No Label: Luka Kulic, MD In this episode, Luka Kulic, MD, Vice President and Global Head of Early Clinical Development in Neuroscience and Rare Diseases at Roche, Basel, Switzerland, discusses the investigational Brainshuttle technology, including results from the BrainShuttle AD clinical trial s as a treatment for early Alzheimer disease along with the broader implications of enhanced blood-brain barrier drug delivery in neurology.

Publishing over time

Last 90 days. Choose a month to open its work.

Recurring subjects

Named in the text we hold. One piece can cover several.

Not enough subject data for this period yet.

Audience

No verified audience measurement yet.

About this data

Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.

Identity or attribution wrong? Suggest a correction.

See coverage about NeuroFrontiers